Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
By simultaneously aiming at GLP-1, GIP, and glucagon receptors, these drugs, such as retatrutide, deliver significantly greater efficacy than current therapies, expanding the addressable patient base
Overview New York, NY Nov 27, 2025 Global GLP-1 Receptor Agonist Market size is expected to be worth around US$ 268.4 billion by 2034 from US$ 53.5 billion in 2024, growing at a CAGR of 17.5% during the forecast period 2025 to 2034
Of the 710 patients with Type 2 diabetes studied, the NAION incident was 8.9% for those taking semaglutide compared to 1.8% for those taking another kind of medication
A family history of premature cardiovascular disease or familial hypercholesterolaemia is particularly relevant
US$ 26.43
US$ 26.97
US$ 23.17
US$ 21.79
US$ 21.72
US$ 26.64
